Qiu, Lugui

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 793

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 271

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells

Hao, M., Zhang, L., An, G., Sui, W., Yu, Z., Zou, D., Xu, Y., Chang, H., & Qiu, L. (2011) · Journal of Hematology & Oncology

Multiple Myeloma Research and TreatmentsMicroRNA in disease regulation

Cited by 77

Low serum mi R‐19a expression as a novel poor prognostic indicator in multiple myeloma

Hao, M., Zang, M., Wendlandt, E., Xu, Y., An, G., Gong, D., Li, F., Qi, F., Zhang, Y., Yang, Y., et al. (2015) · International Journal of Cancer

Multiple Myeloma Research and TreatmentsMicroRNA in disease regulation

Cited by 72

B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells

Ge, W., Ma, X., Li, X., Wang, Y., Li, C., Meng, H., Liu, X., Yu, Z., You, S., & Qiu, L. (2009) · Leukemia Research

Immunotherapy and Immune ResponsesT-cell and B-cell Immunology

Cited by 44

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Yu, T., Chaganty, B., Lin, L., Xing, L., Ramakrishnan, B., Wen, K., Hsieh, P. A., Wollacott, A., Viswanathan, K., Adari, H., et al. (2020) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 43

CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1).

Li, C., Wang, D., Song, Y., Huang, H., Li, J., Chen, B., Liu, J., Dong, Y., Hu, K., Liu, P., et al. (2023) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 28

Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma

Li, F., Hao, M., Feng, X., Zang, M., Qin, Y., Yi, S., Li, Z., Xu, Y., Zhou, L., Sui, W., et al. (2015) · Leukemia Research

Multiple Myeloma Research and TreatmentsMicroRNA in disease regulation

Cited by 25

A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Sun, M., Qi, J., Qiu, L., Jin, J., Li, X., Wei, Y., Zhang, G., Liu, X., & Yin, S. (2023) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 5